Because CML chemoresistance is attributed to acquiring of quiescence in the BMM,1 TIAR and FMRP activity could essentially modify leukemia cells’ sensitivity to therapy. Here, FMR1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.